Literature DB >> 30746911

Diabetic Nephropathy in Type 2 Diabetic Retinopathy Requiring Panretinal Photocoagulation.

Minji Ha1, Seung Yong Choi1, Mirinae Kim1, Jong Kyeong Na1, Young Hoon Park1,2.   

Abstract

PURPOSE: To investigate the risk factors of diabetic nephropathy in patients with diabetic retinopathy requiring panretinal photocoagulation (PRP) and the visual prognosis.
METHODS: A retrospective review of electronic medical records was conducted at Seoul St. Mary's Hospital, comprising 103 patients with type 2 diabetes mellitus and diabetic retinopathy who underwent PRP from 1996 to 2005. Patients with type 1 diabetes mellitus, non-diabetic renal disease, non-diabetic retinal disease, visually significant ocular disease, high-risk proliferative diabetic retinopathy, and advanced diabetic retinopathy were excluded. The patients were divided into three groups: no nephropathy (group 1, n = 45), microalbuminuria (group 2, n = 16), and advanced nephropathy (group 3, n = 42). Duration of diagnosis of retinopathy and nephropathy, glycosylated hemoglobin, visual acuity, complications, and treatment history were investigated.
RESULTS: The mean glycosylated hemoglobin of group 3 (8.4 ± 1.2) was higher than that of group 1 (7.7 ± 1.0) or group 2 (7.7 ± 1.0) (p = 0.04). Mean interval from PRP to diagnosis of nephropathy was 8.8 ± 6.0 years in group 2 and 8.7 ± 4.9 years in group 3. The significant decrease in visual acuity in group 3 (28 eyes, 35.9%) was significantly higher than that in group 1 (15 eyes, 18.1%, p = 0.01) or group 2 (6 eyes, 20.7%, p = 0.03). Only vitreous hemorrhage showed a significantly higher incidence in groups 2 and 3 than in group 1 (p = 0.02). Multivariate regression analysis revealed that female sex and lower glycosylated hemoglobin were significantly associated with a protective effect on development of nephropathy.
CONCLUSIONS: In the clinical setting, many patients with PRP-requiring diabetic retinopathy develop nephropathy an average of 8 to 9 years after PRP. Male sex and higher glycosylated hemoglobin could be risk factors of nephropathy.
© 2019 The Korean Ophthalmological Society.

Entities:  

Keywords:  Diabetic nephropathies; Diabetic retinopathy; Panretinal photocoagulation

Mesh:

Year:  2019        PMID: 30746911      PMCID: PMC6372382          DOI: 10.3341/kjo.2018.0034

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  5 in total

1.  Ocular findings, surgery details and outcomes in proliferative diabetic retinopathy patients with chronic kidney disease.

Authors:  Jipeng Li; Aman Chandra; Lin Liu; Lin Zhang; Jun Xu; Meng Zhao
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with diabetic nephropathy.

Authors:  Ronghua Li; Tianting Shi; Enpeng Xing; Hongcui Qu
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

3.  Long-term prediction models for vision-threatening diabetic retinopathy using medical features from data warehouse.

Authors:  Kwanhoon Jo; Dong Jin Chang; Ji Won Min; Young-Sik Yoo; Byul Lyu; Jin Woo Kwon; Jiwon Baek
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

Review 4.  Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis.

Authors:  Seyed Alireza Dastgheib; Farzaneh Najafi; Ahmad Shajari; Reza Bahrami; Fatemeh Asadian; Jalal Sadeghizadeh-Yazdi; Elahe Akbarian; Seyed Alireza Emarati; Hossein Neamatzadeh
Journal:  J Diabetes Metab Disord       Date:  2020-11-03

5.  Evaluation of the andrographolides role and its indoleamine 2,3-dioxygenase inhibitory potential and attendant molecular mechanism against STZ-induced diabetic rats.

Authors:  Munipally Praveen Kumar; Estari Mamidala; Khalid A Al-Ghanim; F Al-Misned; Shahid Mahboob
Journal:  Saudi J Biol Sci       Date:  2019-12-17       Impact factor: 4.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.